Minute Insight: FDA Clears Fujirebio’s IVD For Alzheimer’s Disease
Executive Summary
Fujirebio Diagnostics’ Lumipulse G beta-amyloid ratio test assesses beta-Amyloid pathology in patients with suspected Alzheimer’s disease or other causes of cognitive decline. Lab tests for Alzheimer’s are already available, but this the first in vitro diagnostic for the disease that the agency has authorized.